Neutralizing Dengue Antibodies after 10 years of the Chimeric Yellow Fever Tetravalent Dengue Vaccine (CYD-TDV) and Dengue Antibody Cross-reactivity with SARS-CoV-2 in Indonesia
{{output}}
Background: Dengue endemic countries were affected by the spread of COVID-19. In 2011, Indonesia participated in a multi-center phase III clinical trial of chimeric yellow fever tetravalent dengue vaccine (CYD-TDV). This study ev... ...
